Tonix Pharma AI Stock Analysis
Tonix Pharma (TPM0) AI Stock Analysis
Tonix Pharma
(Frankfurt:TPM0)
No summary available
Tonix Pharma (TPM0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 49.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 42
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.49
- Revenue Growth
- 299.05%
- EPS Growth
- 98.86%
- Country
- Germany
- Employees
- 142
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Tonix Pharma Business Overview & Revenue Model
Company Description
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and dia...
Tonix Pharma Earnings Call Summary
The call was predominantly positive, led by strong TONMYA sales and prescription growth, improving payer coverage, rising refills, expanded commercial reach, and continued progress across the clinical pipeline. The main challenges were the Dr. Reddy's Paragraph IV patent challenge, materially higher operating expenses, a declining cash balance, uncertainty around some clinical timelines, and the regulatory impasse for TNX-1300.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects TONMYA’s positive trends to continue into the fourth quarter, with a larger sales force and growing sales, and believes it is “well positioned for a strong fourth quarter and 2027”; the 150-person sales force is targeting roughly 70% of approximately 25,000 HCPs who diagnose and treat fibromyalgia, while coverage reaches approximately 53% of covered lives in the U.S. and is expected to continue expanding. The company expects gross to net fluctuations early in the launch, continued progress in coverage, continued improvement on copay buydowns and approval rates, and “consistent growth” through Q4 through 2027. For TNX-4800, the adaptive Phase II TRAIL study is expected to begin in the first quarter of 2027, enroll approximately 3,300 adults over 2 Lyme seasons, start with a lead-in cohort of approximately 500 participants in the first quarter of 2027, and enroll the balance of the efficacy cohort in the 2028 Lyme season; the company expects safety clearance by the end of the second quarter or early in the third quarter, and expects to begin enrolling in the Phase II study in the first half of 2027. An investigator-initiated Phase II study of TNX-1500 is expected to begin in the first quarter of 2027 at Massachusetts General Hospital, enroll five patients, and has a primary endpoint of 18 months with interim looks at earlier time points. The company expects its cash resources and net proceeds raised from the equity offering after quarter end to meet operating and capital expenditure requirements into early third quarter of 2027, has guided to runway into Q3 of next year, is monitoring expenses and focusing on key programs, and is not yet guiding to HORIZON enrollment completion or top-line timing, although it is hoping to enroll it quickly and provide guidance hopefully sometime soon.
Tonix Pharma Risk Analysis
Tonix Pharma disclosed 71 risk factors in its most recent earnings report. Tonix Pharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksTonix Pharma Peers Comparison
Overall Rating
PLX77Outperform
IPHA50Neutral
FATE42Neutral
AVTX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | $258.02M | 11.14 | 30.74% | ― | 36.96% | 266.67% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $110.92M | -1.62 | 152.56% | ― | -24.21% | 1.17% | |
| 42Neutral | $122.78M | -0.89 | -73.92% | ― | -33.45% | 21.90% | |
| 38Underperform | $390.31M | -2.34 | -34.21% | ― | -69.27% | 66.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:TPM0 | Tonix Pharmaceuticals | 2.46 | -9.84 | -79.96% | |
| PLX | Protalix Biotherapeutics | 2.90 | 1.15 | 65.71% | |
| FATE | Fate Therapeutics Inc | 0.92 | -0.16 | -14.91% | |
| AVTX | Avalo Therapeutics, Inc. | 6.76 | -11.24 | -62.44% | |
| IPHA | Innate Pharma SA Sponsored ADR | 0.86 | -0.95 | -52.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
